The DCGI has granted permissions to Bajaj healthcare to supply 'Ivejaj' in the domestic as well as overseas markets.
‘Indian regulator, the DCGI, has granted permission to Bajaj healthcare to supply ivermectin tablets in the domestic and overseas markets for treating COVID-19.’
Read More..
It is an anti-parasitic drug, which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of COVID-19 patients. It acts by paralyzing and killing parasites.Read More..
Anil Jain, Joint managing director, Bajaj Healthcare said: "We are pleased to add Ivermectin to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Ivejaj will considerably ease the pressure and offer patients much needed and timely therapy option."
Bajaj Healthcare has developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through using it's R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj.
Antiparasitic Ivermectin can End Pandemic
Use of common antiparasitic ivermectin can end COVID-19 pandemic, claimed a peer-reviewed research. The drug significantly reduces the risk of contracting the deadly respiratory disease.
Use of common antiparasitic ivermectin can end COVID-19 pandemic, claimed a peer-reviewed research. The drug significantly reduces the risk of contracting the deadly respiratory disease.
Advertisement
